[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Carol Davila University of Medicine and Pharmacy\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":148},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,76,102,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100626970","perioperative-sepsis-an-epigenetic-perspective-100626970",false,"NCT07442552","Perioperative Sepsis. An Epigenetic Perspective","Impact of Perioperative Sepsis on Inflammatory, Cardiac, Coagulation, and microRNA Profiles in Patients Undergoing Major Abdominal Surgery","PESE","Inclusion Criteria:\n\n* Age ≥18 years\n* Undergoing major abdominal surgery (elective or emergency)\n* Ability to provide written informed consent\n* Availability of biological samples in the preoperative period and within 24 hours postoperatively\n* Preoperative hemodynamic stability\n\nExclusion Criteria:\n\n* Surgical reintervention within 3 months after the index procedure\n* Multiple surgical procedures during the same hospitalization\n* Active chronic infections (HIV, active viral hepatitis, tuberculosis)\n* Autoimmune or systemic inflammatory diseases\n* Chronic immunosuppressive therapy or long-term corticosteroid use\n* Severe hepatic failure (Child-Pugh class C)\n* End-stage renal disease requiring dialysis\n* Severe pre-existing cardiac disease (NYHA class III-IV heart failure)\n* Pregnancy\n* Refusal or inability to provide informed consent","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","2 Days","OBSERVATIONAL","This single-center, prospective, observational study evaluates the impact of perioperative sepsis on inflammatory response, coagulation abnormalities, cardiac dysfunction, and microRNA expression in adult patients undergoing major abdominal surgery. Forty patients are enrolled and classified into septic and non-septic groups according to international sepsis definitions based on SOFA score criteria. Clinical, biochemical, echocardiographic, and molecular parameters, including selected microRNAs, are assessed preoperatively and within the first 24 hours postoperatively. The study aims to characterize pathophysiological differences associated with perioperative sepsis and to explore the potential prognostic value of microRNAs as early biomarkers of postoperative sepsis.",[26],"Sepsis Abdominal",[28,29,30,31],"perioperative sepsis","epigenetics","echocardiography","biochemical markers in sepsis","RECRUITING","2026-02-24",{"date":35,"type":36},"2026-03-02","ACTUAL",{"date":38,"type":36},"2026-01-20",{"date":40,"type":21},"2026-04-10",{"name":42,"class":43},"Carol Davila University of Medicine and Pharmacy","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":44},"100582735","prevalence-of-pancreatic-steatosis-in-pancreatic-cystic-neoplasms-and-pancreatic-adenocarcinoma-100582735","NCT06867172","Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma","The Emerging Issue - Pancreatic Steatosis Prevalence in Pancreatic Cystic Neoplasms and Adenocarcinoma: Insights From a Single-center Retrospective Study","SPACE","Inclusion Criteria:\n\n* Age 18 or older\n* Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size ≥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam).\n\nExclusion Criteria:\n\n* No evidence of written informed consent\n* Patients with contraindications for endoscopy due to comorbidities\n* Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary)\n* Acute pancreatitis at baseline imaging\n* Pancreatic surgery at baseline imaging in our department\n* Splenectomy\n* Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women",true,{"count":55,"type":21},66,"Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS).\n\nThe primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk.\n\nThe secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.",[58,59,60],"Pancreatic Steatosis","Pancreatic Cyst","Pancreatic Adenocarcinoma",[62,63,64,65,66,67],"pancreas","steatosis","cyst","cancer","adenocarcinoma","fat","2025-03-06",{"date":70,"type":36},"2025-03-10",{"date":72,"type":36},"2019-01-01",{"date":74,"type":21},"2025-06-30",{"name":42,"class":43},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":87,"studyType":23,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100518702","endoscopic-submucosal-dissection-registry-100518702","NCT06033976","Endoscopic Submucosal Dissection Registry","Endoscopic Submucosal Dissection Patients Registry in \"Agrippa Ionescu\" Hospital, Bucharest, Romania","ESDREG","Inclusion Criteria:\n\n* epithelial pre-neoplastic (eg. adenoma, dysplasia) lesion on the esophageal, gastric, duodenal or colorectal mucosa\n* non-epithelial (eg. neuroendocrine tumor) lesion on the esophageal, gastric, duodenal or colorectal mucosa\n* age \\> 18 years old\n* informed consent\n\nExclusion Criteria:\n\n* age \\\u003C 18 years old\n* no informed consent","100 Years",{"count":86,"type":21},200,"10 Years","This is a patient registry for all cases of pre-neoplastic or early neoplastic digestive tract lesions treated with curative intention by endoscopic submucosal dissection (ESD) technique.",[90,91,92,93],"Neoplasm, Stomach","Neoplasm, Colorectal","Neoplasm, Esophagus","Neoplasm, Duodenal","2024-11-09",{"date":96,"type":36},"2024-11-12",{"date":98,"type":36},"2021-01-01",{"date":100,"type":21},"2031-01",{"name":42,"class":43},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100568599","smart-gloves-hand-motion-tracking-for-live-endoscopic-submucosal-dissection-training-100568599","NCT06683326","Smart-gloves Hand Motion Tracking for Live Endoscopic Submucosal Dissection Training","Smart-gloves Hand Motion Tracking for Live Endoscopic Submucosal Dissection Training: a Randomized, Comparative Study","EndoHandView","Inclusion Criteria:\n\n* ESD trainees with experience in EMR and difficult polypectomy\n\nExclusion Criteria:\n\n* ESD trainees with previous significant experience in ESD on animal model\n* ESD trainees with previous significant experience in ESD on patients",{"count":111,"type":21},12,"INTERVENTIONAL",[114],"NA","Learning endoscopic submucosal dissection (ESD) is undertaken by experienced endoscopists in endoscopic mucosal resection and management of complications. Understanding the theoretical approach of the procedure and the cutting line is a prerequisite of performing it. The precise knife movements following the cutting line during incision, trimming and dissection takes time to master.\n\nThe European Society of Gastrointestinal Endoscopy (ESGE) recommends certain steps of the learning process: starting on animal models and further passing onto easier cases in patients, all these with expert supervision. Observation of experts directly or in live endoscopy meetings are recommended. Direct observation of the experts allow viewing and understanding the hand and finger movements during the specific ESD procedure phases (incision, trimming, dissection). Conversely, during live endoscopy meetings, one cannot see the hand and fingers movements of the operator. Using motion tracking smart-gloves, these fine movements may be visually broadcasted together with the endoscopic view during live meetings. There currently are no studies on motion tracking of hand and finger movements smart gloves in gastrointestinal endoscopy.\n\nBroadcasting the ESD expert's hands and fingers movements using a motion tracking smart-glove during a live endoscopy event will increase the trainees ESD procedure speed. Concomitantly seeing the endoscopic view and the hand and fingers view, the trainee will establish a relationship between the hand and fingers movement and the effect on the dissected tissue. A faster practical \"how to do it\" formula will hopefully be acquired by the trainee.\n\nAdditional benefits are expected, as a faster trainee learning curve will diminish the carbon footprint of the endoscopic training process.\n\nA prospective randomized study will be implemented to test the research hypothesis. Trainees will be divided in two groups, depending on their view during live ESD procedures performed by the experts: the study group \\[endoscopic view + hand motion view\\] versus the control group \\[only endoscopic view\\]. The experts endoscopists will demonstrate ESD procedures on an animal model. Afterwards, the trainee will perform, under supervision, an ESD procedure on the same animal model. Several parameters will be noted: speed of the procedure, the en-bloc or piece-meal resection, the R0 resection, presence of complications (perforation) and the satisfaction score of the trainee on a numerical visual scale.",[117],"Animal Model","NOT_YET_RECRUITING","2024-11-08",{"date":96,"type":36},{"date":122,"type":21},"2025-05-01",{"date":124,"type":21},"2025-05-31",{"name":42,"class":43},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":44},"100533300","predictive-values-of-presepsin-levels-in-ascites-in-patients-with-chronic-liver-failure-100533300","NCT06224023","Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure","PASS","Inclusion Criteria:\n\n* patient with ascites and chronic liver failure\n* no contraindications and technical possibility to perform diagnostic paracentesis\n* age above 18 years old\n* informed consent\n\nExclusion Criteria:\n\n* contraindications to paracentesis or technical impossibility to perform paracentesis\n* absence of informed consent",{"count":134,"type":21},30,"The investigators aim to study the predictive value of presepsin in ascites in newly admitted patients with chronic liver failure.",[137,138,139],"Ascites Hepatic","Liver Failure","Cirrhosis, Liver","2024-08-20",{"date":142,"type":36},"2024-08-21",{"date":144,"type":36},"2024-08-01",{"date":146,"type":21},"2024-12-31",{"name":42,"class":43},""]